Older women ‘less likely’ to be offered ovarian cancer treatment
An ageing populations means it is vital women of all ages have access to best possible treatments, researchers caution
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Older women could be less likely to receive ovarian cancer treatment.
A new report analysed data from more than 17,000 cases of ovarian cancer diagnosed across England between 2016 and 2018.
Three in five (60 per cent) of women with ovarian cancer over the age of 79 did not receive either chemotherapy or surgery, while 37 per cent of women over the age of 70 did not receive any treatment.
The nature of ovarian cancer means surgery is essential in the large majority of cases to remove the tumour.
The researchers cautioned that with an ageing population it is vital that women of all ages have access to the best possible treatments.
Researchers also examined the various rates of treatments for ovarian cancer among women in different parts of England.
They found the probability of receiving any treatment fell below the average in the East Midlands, the East of England, Greater Manchester and Kent and Medway.
The report was jointly funded by The British Gynaecological Cancer Society, Ovarian Cancer Action, Target Ovarian Cancer and delivered by analysts at the National Cancer Registration and Analysis Service.
Commenting on the report, Cary Wakefield, chief executive of Ovarian Cancer Action, said: "Neither your age nor location should decide your chance of survival if you are diagnosed with ovarian cancer.
"Our audit is the first step in addressing the health inequalities women across England face, so we can begin to dismantle them."
British Gynaecological Cancer Society president, professor Sudha Sundar, added: "We now need a fully funded audit to identify and rectify what factors are responsible for this worrying variation in anticancer treatment received by women across England.
"We know that these factors can be organisational, for example availability of theatre lists or intensive care beds; we will be urging our members to carefully look at this data and discuss this with their hospital trusts."
Annwen Jones, chief executive of Target Ovarian Cancer, said: "Our audit has identified a real opportunity to improve ovarian cancer survival rates in England as we come out of this pandemic.
"It's totally unacceptable that some women are being denied the most effective treatment options based on anything, let alone postcode or age, and these inequalities must be addressed."
Almost 7,000 women are diagnosed with ovarian cancer in England each year.
Only a third (35 per cent) will survive their cancer for more than five years. The UK has one of he lowest ovarian cancer survival rates in Europe, experts said.
Additional reporting by Press Association
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments